Cannvas MedTech (CSE:MTEC), a leading business technology company in the cannabis space, is pleased to announce it is partnering with Pancreatic Cancer Canada to provide free educational content to patients and caregivers across the country curious to learn whether cannabis can be a beneficial part of their treatment.
“Access to physician-backed education around cannabis is crucial for everyone, particularly for patients and caregivers struggling with a disease as frightening as pancreatic cancer,” says Shawn Moniz, Chief Executive Officer of Cannvas MedTech Inc. “Pancreatic Cancer Canada will be able to offer their community an online portal, powered by our Cannvas.Me platform, to share knowledge and experiences about the benefits of using medical cannabis as an alternative health care option, and through this partnership Cannvas will have access to greater research and data to better serve our users going forward.”
Pancreatic Cancer Canada and Cannvas worked together to launch the first round of content on Cannvas.Me to mark National Pancreatic Cancer Awareness Month in November. It remains online at Cannvas.Me/PancreaticCancer as part of the Cannvas Health Advocacy Team (CHAT) initiative, designed to delve deeper into health conditions and provide clarity on lesser-known medical ailments affecting large swaths of the population.
The two organizations also plan to collaborate and share resources to create original content contextualized to fit the needs of pancreatic cancer patients and their caregivers. Additional content will be created regularly by both organizations based on community feedback received by Pancreatic Cancer Canada.
“As a national organization dedicated to pancreatic cancer, we play an integral role in ensuring that the patient community and public at large have timely and up-to-date information. Given the very fast progression of this disease for the majority of people who receive a diagnosis, managing symptoms and accessing tools for living as well as they possibly can is paramount. We are excited to work with Cannvas MedTech to bring the Cannvas.Me platform to our community and their healthcare teams as an unbiased, science-based tool for determining if cannabis might a viable option for them.” Michelle Capobianco, Executive Director, Pancreatic Cancer Canada.
Cannvas will enable the wellness and education of the Pancreatic Cancer Canada community through access to its free and unbiased cannabis education resource, Cannvas.Me. The platform features physician-backed content overseen by certified educators for all audiences wishing to learn about whether the benefits of medical or therapeutic cannabis fit their lifestyle.
Pancreatic cancer patients and caregivers will be able to access physician testimonials, patient stories, research papers and educational courses about the potential benefits of medical cannabis. Those interested in enriching their knowledge on the subject will be able to continue their cannabis education with Cannvas through a variety of targeted courses and articles.
“My wife’s family struggled with the loss of her mother to pancreatic cancer and it’s an overwhelming disease to deal with in a very short period of time, creating a real sense of urgency around the comfort and wellness of the patient,” said Steve Loutskou, Chief Operating Officer, Global Markets for Cannvas MedTech Inc. “We are looking forward to helping create an outlet of distribution for education around the potential benefits medical cannabis can provide pancreatic cancer patients, from pain relief to increased appetite.”
Cannvas was also the main sponsor of the third annual Lip Sync Battles Cancer fundraiser in support of Pancreatic Cancer Canada that took place in Montreal on Saturday, November 24 at the Phi Centre, a meticulously restored heritage building located at 407 Rue Saint-Pierre in Old Montreal. Hosted by Michael Musi, a Montreal-born-and-raised actor who can be found playing Terence on the hit CBC show “Kim’s Convenience”, the fundraiser featured local talent raising awareness and an amazing $19,000 for this cancer.
About Pancreatic Cancer Canada
Pancreatic Cancer Canada is the only national organization devoted to fighting pancreatic cancer through research, awareness, education and advocacy. Our goals are to improve overall patient survival rates, change the outcomes and create a brighter future for those affected by pancreatic cancer. For more information about the Pancreatic Cancer Canada Foundation: PancreaticCancerCanada.ca
About Lip Sync Battles
Lip Sync Battles Cancer was born three years ago when co-founders Marianne Musi and Vince Colletti decided to have a get-together with friends and host a Lip Sync Battle. The idea flourished into a fundraising event where all proceeds go to Pancreatic Cancer Canada. Michael and Marianne Musi are extremely passionate about raising funds for pancreatic cancer since it took their 52-year-old mother a little over five years ago. Event Details: https://www.facebook.com/events/393570737841946/
About Cannvas MedTech Inc.
Cannvas MedTech is a leading business technology company in the cannabis space. We design and build customer-centric solutions that enable our partners to harness the power of data to truly understand their customers, industry, and key business drivers.
No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.
Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted onwww.sedar.com.
For further information: www.cannvasmedtech.com, Media Inquiries: email@example.com; Investor Relations: firstname.lastname@example.org, 1-800-489-0116
Aion Therapeutic Inc. (CSE: AION) (” Aion Therapeutic ” or the ” Company “) today announced that it has retained KCSA Strategic Communications (” KCSA “), a leading New York City -based communications firm.
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), today announced the closing of its previously announced marketed public offering of 5,000,000 subordinate voting shares in the United States and Canada (the “Offering”) at a public offering price of C$50.00 per share ( $39.63 per share after giving effect to the conversion rate published by Bloomberg at 4:30pm ET on April 7, 2021 to convert Canadian dollars to U.S. dollars). In connection with the closing of the Offering, the underwriters exercised in full their option to purchase an additional 750,000 subordinate voting shares. As a result, the gross proceeds from the Offering, before deducting underwriting discounts and commissions and offering expenses payable by Trulieve, were C$287.5 million (or $227.9 million after giving effect to the conversion rate denoted above).
The Offering was conducted through a syndicate of underwriters led by Canaccord Genuity, as sole book-running manager, and included Cormark Securities Inc., as co-lead manager, as well as ATB Capital Markets Inc., Echelon Wealth Partners Inc., Eight Capital and PI Financial Corp. All of the shares in the Offering were sold by Trulieve. Trulieve intends to use the net proceeds from the Offering primarily to fund Trulieve’s business development and for general working capital purposes.
Ayurcann Holdings Corp. ( CSE: AYUR ) (the “ Company ” or “ Ayurcann ”), is pleased to announce that the Company intends to complete a non-brokered private placement (the “Financing” ) of up to 2,645,503 units (the “Units” ) at a price of $0.189 per Unit. Each Unit will consist of one common share ( “Common Share” ) of the Company and one-half of a common share purchase warrant ( “Warrant” ), with each whole Warrant entitling the holder to acquire one additional Common Share at an exercise price of $0.38 per Common Share for a period of 36 months from the closing date ( “Closing Date” ) of the Financing, for gross proceeds of up to $500,000 .
The Company will have an option, prior to the closing date, to upsize the offering with the sale of an additional 25% of Units, accounting to aggregate proceeds of up to $625,000.
Lobe invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation at the Emerging Growth Conference
Nextleaf Solutions Receives Amendment to Standard Processing Licence to Allow for Direct to Province Sales
Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) (“Nextleaf”, “OILS”, or the “Company”), the world’s most innovative cannabis processor, is pleased to announce that its wholly-owned subsidiary, Nextleaf Labs Ltd. (“Nextleaf Labs”), has received an amendment to its existing Standard Cannabis Processing Licence from Health Canada (the “Amendment” or the “Amended Licence”) that authorizes the sale of cannabis extracts, edibles, and topical products, directly to provincially-authorized distributors and retailers across Canada.